Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent 50% Three-Month Share Price Rally

Crinetics Pharmaceuticals (CRNX) shares have shown impressive movement over the past three months, rising 50 percent. Investors are watching closely as the company’s performance stands out in the biotechnology sector this quarter.

See our latest analysis for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has staged a remarkable turnaround after a tough start to the year. Over the last 90 days, the company has delivered a 50 percent share price gain, which stands in stark contrast to its 1-year total shareholder return of -23 percent. This momentum suggests renewed optimism around the company’s prospects, especially following some positive signals in the sector, and indicates that investor sentiment may be shifting in favor of future growth.

Looking to discover more in the healthcare space? Now’s a great time to check out See the full list for free.

With such a rapid rebound, the big question facing investors is whether Crinetics Pharmaceuticals still has room to run or if the market has already anticipated this momentum, making further gains harder to come by.

Price-to-Book of 3.4x: Is it justified?

Crinetics Pharmaceuticals is currently trading at a price-to-book ratio of 3.4x, which falls below its peer average of 7x. This suggests the stock appears cheap relative to similar companies in the pharmaceuticals and biotech sector, based on this specific valuation metric.

The price-to-book ratio is a commonly used measure for companies, especially in sectors where profits may not yet be material, like biotech. It compares a company's market value to its book value, offering a snapshot of how the market is assessing future growth potential or asset strength relative to peers.

At 3.4x, Crinetics looks undervalued when contrasted with its peer group but more expensive than the broader US Pharmaceuticals industry average of 2.3x. This disparity may indicate that investors expect strong future growth from Crinetics, which could justify the premium to the wider industry, yet the valuation still lags behind top peers. However, keep in mind that Crinetics is currently unprofitable, and valuation based on book value rather than earnings is typical in early-stage biotech. If the market shifts its fair ratio expectations, the multiple could adjust accordingly.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 3.4x (UNDERVALUED)

However, investors must consider that unprofitability and sharp recent gains could bring volatility or swift sentiment reversals if expectations are not met.

Find out about the key risks to this Crinetics Pharmaceuticals narrative.

Another View: Discounted Cash Flow Perspective

Beyond simple book value comparisons, our DCF model values Crinetics Pharmaceuticals at $112.31 per share, well above its recent price of $42.90. This points to a much deeper undervaluation than what the price-to-book ratio suggests, but it also relies heavily on long-term growth projections that could shift rapidly. Which perspective will play out in the market?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Crinetics Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 856 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Crinetics Pharmaceuticals Narrative

If you have a different perspective or would rather form your own view, you can analyze the numbers and assemble a narrative yourself in just minutes. Do it your way

A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Give your portfolio an edge by taking action on emerging opportunities outside the mainstream. Don’t wait until everyone catches on—these ideas could be tomorrow’s leaders.

• Capture steady income streams by checking out these 21 dividend stocks with yields > 3% with robust yields and financial health for reliable returns.
• Spot potential tech disruptors by investigating these 26 AI penny stocks at the intersection of artificial intelligence and industry innovation.
• Seize value opportunities with these 856 undervalued stocks based on cash flows signaling attractive prices relative to future growth prospects and cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com